Established and new-generation antithrombotic drugs in patients with cirrhosis - Possibilities and caveats

Journal of Hepatology

Volumn 59, Issue 2, 2013, Pages 358-366

  Lisman, Ton ^a   Kamphuisen, Pieter W ^b   Northup, Patrick G ^c   Porte, Robert J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Anticoagulant drugs; Arterial thrombosis; Cirrhosis; Portal vein thrombosis; Thrombosis; Treatment; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; PRASUGREL; RIVAROXABAN; TICAGRELOR;

ARTERY THROMBOSIS; ASCITES; BLEEDING; BRAIN INFARCTION; CHRONIC LIVER DISEASE; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LUNG EMBOLISM; NONHUMAN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL TIME; THROMBOSIS;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANTICOAGULANT DRUGS; APTT; ARTERIAL THROMBOSIS; CIRRHOSIS; DEEP VEIN THROMBOSIS; DVT; GASTROINTESTINAL; GI; HEPARIN-INDUCED THROMBOCYTOPENIA; HIT; INR; INTERNATIONAL NORMALIZED RATIO; LMWH; LOW MOLECULAR WEIGHT HEPARIN; NAFLD; NASH; NON-ALCOHOLIC FATTY LIVER DISEASE; NON-ALCOHOLIC STEATOHEPATITIS; PORTAL VEIN THROMBOSIS; PROTHROMBIN TIME; PT; PVT; THROMBOSIS; TREATMENT; VENOUS THROMBOSIS; VITAMIN K ANTAGONISTS; VKA;

ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DISEASE PROGRESSION; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; LIVER CIRRHOSIS; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; THROMBOSIS; VITAMIN K;

EID: 84880256623     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.027     Document Type: Review

References (67)

1. T. Lisman, and R.J. Porte Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences Blood 116 2010 878 885
2. A. Tripodi, and P.M. Mannucci The coagulopathy of chronic liver disease N Engl J Med 365 2011 147 156
3. A. Tripodi, Q.M. Anstee, K.K. Sogaard, M. Primignani, and D.C. Valla Hypercoagulability in cirrhosis: causes and consequences J Thromb Haemost 9 2011 1713 1723
4. P.G. Northup, V. Sundaram, M.B. Fallon, K.R. Reddy, R.A. Balogun, and A.J. Sanyal Hypercoagulation and thrombophilia in liver disease J Thromb Haemost 6 2008 2 9
5. T. Lisman, S.H. Caldwell, A.K. Burroughs, P.G. Northup, M. Senzolo, and R.T. Stravitz Hemostasis and thrombosis in patients with liver disease: the ups and downs J Hepatol 53 2010 362 371
6. E.A. Tsochatzis, M. Senzolo, G. Germani, A. Gatt, and A.K. Burroughs Systematic review: portal vein thrombosis in cirrhosis Aliment Pharmacol Ther 31 2010 366 374
7. K.I. Rodriguez-Castro, R.J. Porte, E. Nadal, G. Germani, P. Burra, and M. Senzolo Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review Transplantation 94 2012 1145 1153
8. M. Senzolo, T. M. Sartori, V. Rossetto, P. Burra, U. Cillo, and P. Boccagni Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis Liver Int 32 2012 919 927
9. M.G. Delgado, S. Seijo, I. Yepes, L. Achecar, M.V. Catalina, and A. Garcia-Criado Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis Clin Gastroenterol Hepatol 10 2012 776 783
10. L. Amitrano, M.A. Guardascione, A. Menchise, R. Martino, M. Scaglione, and S. Giovine Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis J Clin Gastroenterol 44 2010 448 451
11. C. Francoz, J. Belghiti, V. Vilgrain, D. Sommacale, V. Paradis, and B. Condat Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation Gut 54 2005 691 697
12. Q.M. Anstee, M. Wright, R. Goldin, and M.R. Thursz Parenchymal extinction: coagulation and hepatic fibrogenesis Clin Liver Dis 13 2009 117 126
13. E. Villa, C. Camma, M. Marietta, M. Luongo, R. Critelli, and S. Colopi Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis Gastroenterology 143 2012 1253 1260
14. V. De Ledinghen, D. Heresbach, O. Fourdan, P. Bernard, M.P. Liebaert-Bories, and J.B. Nousbaum Anti-inflammatory drugs and variceal bleeding: a case-control study Gut 44 1999 270 273
15. K.K. Sogaard, E. Horvath-Puho, H. Gronbaek, P. Jepsen, H. Vilstrup, and H.T. Sorensen Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study Am J Gastroenterol 104 2009 96 101
16. P.G. Northup, M.M. McMahon, A.P. Ruhl, S.E. Altschuler, A. Volk-Bednarz, and S.H. Caldwell Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism Am J Gastroenterol 101 2006 1524 1528 quiz 1680
17. A. Aldawood, Y. Arabi, A. Aljumah, A. Alsaadi, A. Rishu, and H. Aldorzi The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients Thromb J 9 2011 1
18. M.J. Garcia-Fuster, N. Abdilla, M.J. Fabia, C. Fernandez, V. Oliver, and M.J. Forner Venous thromboembolism and liver cirrhosis Rev Esp Enferm Dig 100 2008 259 262
19. J.A. Heit, M.D. Silverstein, D.N. Mohr, T.M. Petterson, W.M. O'Fallon, and L.J. Melton 3rd Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 2000 809 815
20. G.H. Guyatt, E.A. Akl, M. Crowther, D.D. Gutterman, H.J. Schuunemann, and American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines Chest 141 2012 7S 47S
21. N.M. Intagliata, Z.H. Henry, N. Shah, S.H. Caldwell, and P.G. Northup Prophylactic anticoagulation for deep venous thrombosis in hospitalized cirrhosis patients is safe and does not lead to increased bleeding events Hepatology 54 2011 1253a
22. M. Melato, E. Mucli, F. Poldrugo, M. Valente, F. Zanconati, and K. Okuda Stroke-cirrhosis relationship: an autopsy study in a heavy drinking population Ital J Gastroenterol 23 1991 211 214
23. W.L. Howell, and W.C. Manion The low incidence of myocardial infarction in patients with portal cirrhosis of the liver: a review of 639 cases of cirrhosis of the liver from 17,731 autopsies Am Heart J 60 1960 341 344
24. G. Marchesini, M. Ronchi, G. Forlani, E. Bugianesi, G. Bianchi, and A. Fabbri Cardiovascular disease in cirrhosis - a point-prevalence study in relation to glucose tolerance Am J Gastroenterol 94 1999 655 662
25. E. Kalaitzakis, A. Rosengren, T. Skommevik, and E. Bjornsson Coronary artery disease in patients with liver cirrhosis Dig Dis Sci 55 2010 467 475
26. S. Patel, T.L. Kiefer, A. Ahmed, Z.A. Ali, J.A. Tremmel, and D.P. Lee Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease Am J Cardiol 108 2011 1552 1555
27. N.C. McAvoy, N. Kochar, G. McKillop, D.E. Newby, and P.C. Hayes Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation Liver Transpl 14 2008 1725 1731
28. C.K. Argo, and S.H. Caldwell Epidemiology and natural history of non-alcoholic steatohepatitis Clin Liver Dis 13 2009 511 531
29. K. Fujita, Y. Nozaki, K. Wada, M. Yoneda, H. Endo, and H. Takahashi Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease Gut 57 2008 1583 1591
30. P.E. Ganey, J.P. Luyendyk, S.W. Newport, T.M. Eagle, J.F. Maddox, and N. Mackman Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice Hepatology 46 2007 1177 1186
31. Q.M. Anstee, R.D. Goldin, M. Wright, A. Martinelli, R. Cox, and M.R. Thursz Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies J Thromb Haemost 6 2008 1336 1343
32. M. Wright, R. Goldin, S. Hellier, S. Knapp, A. Frodsham, and B. Hennig Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection Gut 52 2003 1206 1210
33. N. Assy, N. Pettigrew, S.S. Lee, R.K. Chaudhary, J. Johnston, and G.Y. Minuk Are chronic hepatitis C viral infections more benign in patients with hemophilia? Am J Gastroenterol 102 2007 1672 1676
34. M. Cattaneo Resistance to anti-platelet agents Thromb Res 127 2011 S61 S63
35. G.G. Hugenholtz, R.J. Porte, and T. Lisman The platelet and platelet function testing in liver disease Clin Liver Dis 13 2009 11 20
36. W.F. Miser Appropriate aspirin use for primary prevention of cardiovascular disease Am Fam Physician 83 2011 1380 1386
37. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
38. M.W. Russo, J. Pierson, T. Narang, A. Montegudo, L. Eskind, and S. Gulati Coronary artery stents and antiplatelet therapy in patients with cirrhosis J Clin Gastroenterol 46 2012 339 344
39. C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, and J.P. Collet Antiplatelet agents for the treatment and prevention of atherothrombosis Eur Heart J 32 2011 2922 2932
40. M. Cattaneo New P2Y(12) inhibitors Circulation 121 2010 171 179
41. P.H. Slugg, D.R. Much, W.B. Smith, R. Vargas, P. Nichola, and J. Necciari Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel J Clin Pharmacol 40 2000 396 401
42. D.S. Small, N.A. Farid, Y.G. Li, C.S. Ernest 2nd, K.J. Winters, and D.E. Salazar Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease J Clin Pharm Ther 34 2009 575 583
43. K. Butler, and R. Teng Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment J Clin Pharmacol 51 2011 978 987
44. I.R. Wanless, J. Belgiorno, and P.M. Huet Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole Hepatology 24 1996 855 864
45. G. Sansoe, A. Ferrari, P. D'Alimonte, T. Trenti, P. Zoboli, and R. Romagnoli Beneficial hemodynamic effects of dipyridamole on portal circulation in cirrhosis Am J Gastroenterol 93 1998 429 433
46. J. Llach, P. Gines, V. Arroyo, J.M. Salmeron, A. Gines, and W. Jimenez Effect of dipyridamole on kidney function in cirrhosis Hepatology 17 1993 59 64
47. M. Schindewolf, E. Lindhoff-Last, R.J. Ludwig, and W.H. Boehncke Heparin-induced skin lesions Lancet 380 2012 1867 1879
48. L.P. Bechmann, M. Sichau, M. Wichert, G. Gerken, K. Kroger, and P. Hilgard Low-molecular-weight heparin in patients with advanced cirrhosis Liver Int 31 2011 75 82
49. M. Senzolo, K.I. Rodriguez-Castro, V. Rossetto, C. Radu, S. Gavasso, and P. Carraro Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis J Thromb Haemost 10 2012 1823 1829
50. T. Lisman, and R.J. Porte Towards a rational use of low-molecular-weight heparin in patients with cirrhosis Liver Int 31 2011 1063
51. A. Tripodi, T. Baglin, A. Robert, S. Kitchen, T. Lisman, and J.F. Trotter Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease J Thromb Haemost 8 2010 1410 1412
52. R.J. Porte, T. Lisman, A. Tripodi, S.H. Caldwell, J.F. Trotter, and Coagulation in Liver Disease Study Group The international normalized ratio (INR) in the MELD score: problems and solutions Am J Transplant 10 2010 1349 1353
53. T. Lisman, Y. van Leeuwen, J. Adelmeijer, I.T. Pereboom, E.B. Haagsma, and A.P. van den Berg Interlaboratory variability in assessment of the model of end-stage liver disease score Liver Int 28 2008 1344 1351
54. A. Tripodi, V. Chantarangkul, M. Primignani, F. Fabris, A. Dell'Era, and C. Sei The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation Hepatology 46 2007 520 527
55. M. Levi, G.K. Hovingh, S.C. Cannegieter, M. Vermeulen, H.R. Buller, and F.R. Rosendaal Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based Blood 111 2008 4471 4476
56. S. Schulman, and M.A. Crowther How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch Blood 119 2012 3016 3023
57. D. Kubitza, A. Roth, M. Becka, A. Alatrach, A. Halabi, and H. Hinrichsen Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban - an oral, direct Factor Xa inhibitor Br J Clin Pharmacol 2013
58. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
59. J. Graff, and S. Harder Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment Clin Pharmacokinet 52 2013 243 254
60. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
61. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J.L. Crackowski, and G. Pernod Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers Thromb Haemost 108 2012 217 224
62. J. Stangier, H. Stahle, K. Rathgen, W. Roth, and K. Shakeri-Nejad Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment J Clin Pharmacol 48 2008 1411 1419
63. J. Stangier, K. Rathgen, H. Stahle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
64. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, and M. Feuring Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
65. S. Blech, T. Ebner, E. Ludwig-Schwellinger, J. Stangier, and W. Roth The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Dispos 36 2008 386 399
66. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
67. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, and H. Stahle Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 2005 555 563